ID   PAPOA_BOVIN             Reviewed;         739 AA.
AC   P25500;
DT   01-MAY-1992, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   22-JUL-2015, entry version 134.
DE   RecName: Full=Poly(A) polymerase alpha;
DE            Short=PAP-alpha;
DE            EC=2.7.7.19;
DE   AltName: Full=Polynucleotide adenylyltransferase alpha;
GN   Name=PAPOLA; Synonyms=PAP;
OS   Bos taurus (Bovine).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Laurasiatheria; Cetartiodactyla; Ruminantia;
OC   Pecora; Bovidae; Bovinae; Bos.
OX   NCBI_TaxID=9913;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORMS LONG AND SHORT), AND PROTEIN
RP   SEQUENCE OF 1-21; 207-255 AND 386-397.
RC   TISSUE=Thymus;
RX   PubMed=1756732;
RA   Wahle E., Martin G., Schiltz E., Keller W.;
RT   "Isolation and expression of cDNA clones encoding mammalian poly(A)
RT   polymerase.";
RL   EMBO J. 10:4251-4257(1991).
RN   [2]
RP   SEQUENCE REVISION.
RA   Wahle E.;
RL   Submitted (AUG-1992) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 97-103 AND
RP   445-468.
RC   TISSUE=Heart muscle;
RX   PubMed=1896071; DOI=10.1038/353229a0;
RA   Raabe T., Bollum F.J., Manley J.L.;
RT   "Primary structure and expression of bovine poly(A) polymerase.";
RL   Nature 353:229-234(1991).
RN   [4]
RP   DOMAINS, AND MUTAGENESIS OF ASP-113; ASP-115; 162-ASP-GLY-163;
RP   ASP-167; ASP-186; ASP-194; ASP-208; GLU-209; GLU-291; GLU-292;
RP   431-GLU-GLU-432; ASP-455; ASP-459 AND ASP-465.
RX   PubMed=8665867;
RA   Martin G., Keller W.;
RT   "Mutational analysis of mammalian poly(A) polymerase identifies a
RT   region for primer binding and catalytic domain, homologous to the
RT   family X polymerases, and to other nucleotidyltransferases.";
RL   EMBO J. 15:2593-2603(1996).
RN   [5]
RP   PHOSPHORYLATION, AND FUNCTION.
RX   PubMed=9463383; DOI=10.1093/emboj/17.4.1053;
RA   Colgan D.F., Murthy K.G., Zhao W., Prives C., Manley J.L.;
RT   "Inhibition of poly(A) polymerase requires p34cdc2/cyclin B
RT   phosphorylation of multiple consensus and non-consensus sites.";
RL   EMBO J. 17:1053-1062(1998).
RN   [6]
RP   ACETYLATION AT LYS-635; LYS-644; LYS-730 AND LYS-734, INTERACTION WITH
RP   NUDT21 AND KPBN1, SUBCELLULAR LOCATION, IDENTIFICATION BY MASS
RP   SPECTROMETRY, AND MUTAGENESIS OF LYS-635; LYS-644; LYS-730 AND
RP   LYS-734.
RX   PubMed=17172643; DOI=10.1074/jbc.M609745200;
RA   Shimazu T., Horinouchi S., Yoshida M.;
RT   "Multiple histone deacetylases and the CREB-binding protein regulate
RT   pre-mRNA 3'-end processing.";
RL   J. Biol. Chem. 282:4470-4478(2007).
RN   [7]
RP   X-RAY CRYSTALLOGRAPHY (2.5 ANGSTROMS) OF 1-513 IN COMPLEX WITH ATP
RP   ANALOG AND MANGANESE IONS.
RX   PubMed=10944102; DOI=10.1093/emboj/19.16.4193;
RA   Martin G., Keller W., Doublie S.;
RT   "Crystal structure of mammalian poly(A) polymerase in complex with an
RT   analog of ATP.";
RL   EMBO J. 19:4193-4203(2000).
RN   [8]
RP   X-RAY CRYSTALLOGRAPHY (2.15 ANGSTROMS) OF 1-513 IN COMPLEX WITH
RP   MAGNESIUM IONS; MANGANESE IONS AND ATP ANALOG, BIOPHYSICOCHEMICAL
RP   PROPERTIES, CATALYTIC ACTIVITY, COFACTOR, AND MUTAGENESIS OF PHE-100;
RP   PHE-153; VAL-156; ASP-167; ARG-199; ASN-202; GLY-203; LYS-228;
RP   LYS-232; TYR-237 AND VAL-247.
RX   PubMed=15328606; DOI=10.1016/j.jmb.2004.06.047;
RA   Martin G., Moglich A., Keller W., Doublie S.;
RT   "Biochemical and structural insights into substrate binding and
RT   catalytic mechanism of mammalian poly(A) polymerase.";
RL   J. Mol. Biol. 341:911-925(2004).
CC   -!- FUNCTION: Polymerase that creates the 3'-poly(A) tail of mRNA's.
CC       Also required for the endoribonucleolytic cleavage reaction at
CC       some polyadenylation sites. May acquire specificity through
CC       interaction with a cleavage and polyadenylation specificity factor
CC       (CPSF) at its C-terminus. {ECO:0000250|UniProtKB:P51003,
CC       ECO:0000269|PubMed:9463383}.
CC   -!- CATALYTIC ACTIVITY: ATP + RNA(n) = diphosphate + RNA(n+1).
CC       {ECO:0000269|PubMed:15328606}.
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420;
CC         Evidence={ECO:0000269|PubMed:15328606};
CC       Name=Mn(2+); Xref=ChEBI:CHEBI:29035;
CC         Evidence={ECO:0000269|PubMed:15328606};
CC       Note=Binds 2 magnesium ions. Also active with manganese.
CC       {ECO:0000269|PubMed:15328606};
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       Kinetic parameters:
CC         KM=0.229 mM for ATP {ECO:0000269|PubMed:15328606};
CC   -!- SUBUNIT: Monomer (PubMed:10944102, PubMed:15328606). Found in a
CC       complex with CPSF1, FIP1L1 and PAPOLA. Interacts with AHCYL1 and
CC       FIP1L1; the interaction with AHCYL1 seems to increase interaction
CC       with FIP1L1 (By similarity). Interacts with NUDT21; the
CC       interaction is diminished by acetylation (PubMed:17172643).
CC       Interacts with KPNB1; the interaction promotes PAP nuclear import
CC       and is inhibited by acetylation of PAP (PubMed:17172643).
CC       {ECO:0000250|UniProtKB:P51003, ECO:0000250|UniProtKB:Q61183,
CC       ECO:0000269|PubMed:10944102, ECO:0000269|PubMed:15328606,
CC       ECO:0000269|PubMed:17172643}.
CC   -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000269|PubMed:17172643}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC         Comment=Additional isoforms seem to exist.;
CC       Name=Long;
CC         IsoId=P25500-1; Sequence=Displayed;
CC       Name=Short;
CC         IsoId=P25500-2; Sequence=VSP_004524, VSP_004525, VSP_004526;
CC         Note=No experimental confirmation available.;
CC   -!- PTM: Polysumoylated. Varying sumolyation depending on tissue- and
CC       cell-type. Highly sumoylated in bladder and NIH 3T3 cells.
CC       Sumoylation is required for nuclear localization and enhances PAP
CC       stability. Desumoylated by SENP1. Inhibits polymerase activity (By
CC       similarity). {ECO:0000250}.
CC   -!- PTM: Hyperphosphorylation on multiple CDK2 consensus and non-
CC       consensus sites in the C-terminal Ser/Thr-rich region represses
CC       PAP activity in late M-phase. Phosphorylation/dephosphorylation
CC       may regulate the interaction between PAP and CPSF (By similarity).
CC       {ECO:0000250}.
CC   -!- PTM: Acetylated in the C-terminus. Acetylation decreases
CC       interaction with NUDT21 and KPNB1, and inhibits nuclear
CC       localization through inhibiting binding to the importin alpha/beta
CC       complex. {ECO:0000269|PubMed:17172643}.
CC   -!- SIMILARITY: Belongs to the poly(A) polymerase family.
CC       {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; X61585; CAA43782.1; -; mRNA.
DR   EMBL; X63436; CAA45031.1; -; mRNA.
DR   PIR; S17875; S17875.
DR   PIR; S17925; S17925.
DR   PIR; S18642; S18642.
DR   RefSeq; NP_788820.1; NM_176647.2. [P25500-1]
DR   UniGene; Bt.109586; -.
DR   PDB; 1F5A; X-ray; 2.50 A; A=1-513.
DR   PDB; 1Q78; X-ray; 2.80 A; A=1-514.
DR   PDB; 1Q79; X-ray; 2.15 A; A=1-514.
DR   PDBsum; 1F5A; -.
DR   PDBsum; 1Q78; -.
DR   PDBsum; 1Q79; -.
DR   ProteinModelPortal; P25500; -.
DR   SMR; P25500; 19-498.
DR   STRING; 9913.ENSBTAP00000005300; -.
DR   PRIDE; P25500; -.
DR   Ensembl; ENSBTAT00000005300; ENSBTAP00000005300; ENSBTAG00000004054. [P25500-1]
DR   GeneID; 338051; -.
DR   KEGG; bta:338051; -.
DR   CTD; 10914; -.
DR   eggNOG; COG5186; -.
DR   GeneTree; ENSGT00390000017928; -.
DR   HOGENOM; HOG000204376; -.
DR   HOVERGEN; HBG053502; -.
DR   InParanoid; P25500; -.
DR   KO; K14376; -.
DR   OMA; EEYRTMW; -.
DR   TreeFam; TF300842; -.
DR   BRENDA; 2.7.7.19; 908.
DR   Reactome; REACT_311099; mRNA Splicing - Major Pathway.
DR   Reactome; REACT_339317; mRNA 3'-end processing.
DR   Reactome; REACT_342878; Processing of Intronless Pre-mRNAs.
DR   Reactome; REACT_351678; Cleavage of Growing Transcript in the Termination Region.
DR   EvolutionaryTrace; P25500; -.
DR   NextBio; 20812502; -.
DR   Proteomes; UP000009136; Chromosome 21.
DR   ExpressionAtlas; P25500; baseline.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005654; C:nucleoplasm; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IDA:UniProtKB.
DR   GO; GO:0000287; F:magnesium ion binding; IDA:UniProtKB.
DR   GO; GO:0030145; F:manganese ion binding; IDA:UniProtKB.
DR   GO; GO:0004652; F:polynucleotide adenylyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0003723; F:RNA binding; IEA:UniProtKB-KW.
DR   GO; GO:0006378; P:mRNA polyadenylation; ISS:UniProtKB.
DR   GO; GO:0031440; P:regulation of mRNA 3'-end processing; ISS:UniProtKB.
DR   GO; GO:0043631; P:RNA polyadenylation; IDA:UniProtKB.
DR   Gene3D; 3.30.70.590; -; 1.
DR   InterPro; IPR002934; Nucleotidyltransferase.
DR   InterPro; IPR011068; NuclTrfase_I_C.
DR   InterPro; IPR007012; PolA_pol_cen_dom.
DR   InterPro; IPR007010; PolA_pol_RNA-bd_dom.
DR   InterPro; IPR014492; PolyA_polymerase.
DR   PANTHER; PTHR10682; PTHR10682; 1.
DR   Pfam; PF01909; NTP_transf_2; 1.
DR   Pfam; PF04928; PAP_central; 1.
DR   Pfam; PF04926; PAP_RNA-bind; 1.
DR   PIRSF; PIRSF018425; PolyA_polymerase; 1.
DR   SUPFAM; SSF55003; SSF55003; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Alternative splicing; ATP-binding;
KW   Complete proteome; Direct protein sequencing; Isopeptide bond;
KW   Magnesium; Manganese; Metal-binding; mRNA processing;
KW   Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   RNA-binding; Transferase; Ubl conjugation.
FT   CHAIN         1    739       Poly(A) polymerase alpha.
FT                                /FTId=PRO_0000051611.
FT   NP_BIND     100    102       ATP.
FT   NP_BIND     113    115       ATP.
FT   NP_BIND     246    247       ATP.
FT   REGION      508    643       Ser/Thr-rich.
FT   REGION      671    739       Required for interaction with NUDT21.
FT   MOTIF       490    507       Nuclear localization signal 1.
FT   MOTIF       644    659       Nuclear localization signal 2.
FT   METAL       113    113       Magnesium 1; catalytic.
FT   METAL       113    113       Magnesium 2; catalytic.
FT   METAL       115    115       Magnesium 1; catalytic.
FT   METAL       115    115       Magnesium 2; catalytic.
FT   METAL       167    167       Magnesium 2; catalytic.
FT   BINDING     109    109       ATP.
FT   BINDING     167    167       ATP.
FT   BINDING     228    228       ATP.
FT   BINDING     237    237       ATP.
FT   SITE        153    153       Interaction with RNA. {ECO:0000250}.
FT   SITE        158    158       Interaction with RNA. {ECO:0000250}.
FT   SITE        328    328       Interaction with RNA. {ECO:0000250}.
FT   SITE        399    399       Interaction with RNA. {ECO:0000250}.
FT   SITE        524    524       Interaction with RNA. {ECO:0000250}.
FT   MOD_RES      24     24       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51003}.
FT   MOD_RES     537    537       Phosphoserine; by MAPK. {ECO:0000250}.
FT   MOD_RES     558    558       Phosphoserine.
FT                                {ECO:0000250|UniProtKB:P51003}.
FT   MOD_RES     635    635       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MOD_RES     644    644       N6-acetyllysine.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MOD_RES     730    730       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MOD_RES     734    734       N6-acetyllysine; alternate.
FT                                {ECO:0000269|PubMed:17172643}.
FT   CROSSLNK    444    444       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000305}.
FT   CROSSLNK    445    445       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000305}.
FT   CROSSLNK    506    506       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000305}.
FT   CROSSLNK    507    507       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO).
FT                                {ECO:0000305}.
FT   CROSSLNK    730    730       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate. {ECO:0000250}.
FT   CROSSLNK    734    734       Glycyl lysine isopeptide (Lys-Gly)
FT                                (interchain with G-Cter in SUMO);
FT                                alternate. {ECO:0000250}.
FT   VAR_SEQ     663    683       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:1756732}.
FT                                /FTId=VSP_004524.
FT   VAR_SEQ     709    710       KT -> II (in isoform Short).
FT                                {ECO:0000303|PubMed:1756732}.
FT                                /FTId=VSP_004525.
FT   VAR_SEQ     711    739       Missing (in isoform Short).
FT                                {ECO:0000303|PubMed:1756732}.
FT                                /FTId=VSP_004526.
FT   MUTAGEN     100    100       F->D: Strongly decreased enzyme activity.
FT                                Strongly reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     113    115       DID->AIA: Abolishes most of the specific
FT                                and non-specific polyadenylation
FT                                activity.
FT   MUTAGEN     113    113       D->H: Abolishes most of the specific and
FT                                non-specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     115    115       D->H: Abolishes most of the specific and
FT                                non-specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     153    153       F->A: Strongly reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     156    156       V->A: Strongly decreased enzyme activity.
FT                                Strongly reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     162    163       DG->HA: Small decrease in non-specific
FT                                and specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     167    167       D->A: Loss of enzyme activity.
FT                                {ECO:0000269|PubMed:15328606,
FT                                ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     167    167       D->H: Abolishes most of the specific and
FT                                non-specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:15328606,
FT                                ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     167    167       D->N: Strongly decreased enzyme activity.
FT                                Strongly reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606,
FT                                ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     186    186       D->H: Small decrease in non-specific and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     194    194       D->H: No change in non-specific and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     199    199       R->A: Strongly reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     202    202       N->A: Strongly decreased enzyme activity.
FT                                Strongly reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     203    203       G->H: Loss of enzyme activity. Strongly
FT                                reduced affinity for RNA.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     208    209       DE->AA: Reduces by 60% non-specific and
FT                                specific polyadenylation activity.
FT   MUTAGEN     208    208       D->A: Reduces by 60% non-specific rf and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     208    208       D->H: Reduces by 20% non-specific and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     209    209       E->A: No change in non-specific and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     228    228       K->A: Strongly decreased affinity for
FT                                ATP. {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     232    232       K->A: Decreased affinity for ATP.
FT                                {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     237    237       Y->A: Strongly decreased affinity for
FT                                ATP. {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     247    247       V->A,R: Strongly reduced affinity for
FT                                RNA. {ECO:0000269|PubMed:15328606}.
FT   MUTAGEN     291    292       EE->AA: Abolishes most of non-specific
FT                                polyadenylation activity.
FT   MUTAGEN     291    291       E->A: Reduces by 60% non-specific
FT                                polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     292    292       E->A: No change in non-specific
FT                                polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     308    308       D->A: No change in non-specific and
FT                                specific polyadenylation activity.
FT   MUTAGEN     317    317       T->G: Strongly decreased affinity for
FT                                ATP.
FT   MUTAGEN     431    432       EE->AA: No change in non-specific and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     455    455       D->A: Reduces by 30% non-specific
FT                                polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     459    459       D->A: No change in non-specific
FT                                polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     465    465       D->A: No change in non-specific and
FT                                specific polyadenylation activity.
FT                                {ECO:0000269|PubMed:8665867}.
FT   MUTAGEN     635    635       K->Q: Weak binding to KPBN1. Cytoplasmic
FT                                location; when associated with Q-644; Q-
FT                                730 and Q-734.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     635    635       K->R: Some decrease in acetylation. Binds
FT                                KPBN1 and localizes to the nucleus; when
FT                                associated with R-644; R-730 and R-734.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     644    644       K->Q: Weak binding to KPBN1. Cytoplasmic
FT                                location; when associated with Q-635; Q-
FT                                730 and Q-734.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     644    644       K->R: Large decrease in acetylation.
FT                                Binds KPBN1 and localizes to the nucleus;
FT                                when associated with R-635; R-730 and R-
FT                                734. {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     730    730       K->Q: Weak binding to KPBN1. Cytoplasmic
FT                                location; when associated with Q-635; Q-
FT                                644 and Q-734.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     730    730       K->R: Some decrease in acetylation. Binds
FT                                KPBN1 and localizes to the nucleus; when
FT                                associated with R-635; R-644 and R-734.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     734    734       K->Q: Weak binding to KPBN1. Cytoplasmic
FT                                location; when associated with Q-635; Q-
FT                                644 and Q-730.
FT                                {ECO:0000269|PubMed:17172643}.
FT   MUTAGEN     734    734       K->R: Some decrease in acetylation. Binds
FT                                KPBN1 and localizes to the nucleus; when
FT                                associated with R-635; R-644 and R-730.
FT                                {ECO:0000269|PubMed:17172643}.
FT   CONFLICT     80     80       S -> R (in Ref. 3; CAA45031).
FT                                {ECO:0000305}.
FT   STRAND       21     23       {ECO:0000244|PDB:1Q79}.
FT   HELIX        33     46       {ECO:0000244|PDB:1Q79}.
FT   HELIX        47     49       {ECO:0000244|PDB:1Q79}.
FT   HELIX        55     82       {ECO:0000244|PDB:1Q79}.
FT   HELIX        87     90       {ECO:0000244|PDB:1Q79}.
FT   STRAND       96    100       {ECO:0000244|PDB:1Q79}.
FT   HELIX       101    105       {ECO:0000244|PDB:1Q79}.
FT   STRAND      114    120       {ECO:0000244|PDB:1Q79}.
FT   HELIX       126    129       {ECO:0000244|PDB:1Q79}.
FT   HELIX       132    138       {ECO:0000244|PDB:1Q79}.
FT   STRAND      143    149       {ECO:0000244|PDB:1Q79}.
FT   STRAND      152    154       {ECO:0000244|PDB:1Q79}.
FT   STRAND      156    161       {ECO:0000244|PDB:1Q79}.
FT   STRAND      164    172       {ECO:0000244|PDB:1Q79}.
FT   STRAND      176    178       {ECO:0000244|PDB:1Q79}.
FT   HELIX       187    190       {ECO:0000244|PDB:1Q79}.
FT   HELIX       195    211       {ECO:0000244|PDB:1Q79}.
FT   STRAND      213    215       {ECO:0000244|PDB:1Q79}.
FT   HELIX       217    233       {ECO:0000244|PDB:1Q79}.
FT   TURN        239    242       {ECO:0000244|PDB:1Q79}.
FT   HELIX       246    259       {ECO:0000244|PDB:1Q79}.
FT   HELIX       265    277       {ECO:0000244|PDB:1Q79}.
FT   TURN        302    304       {ECO:0000244|PDB:1Q79}.
FT   HELIX       306    310       {ECO:0000244|PDB:1Q79}.
FT   STRAND      318    321       {ECO:0000244|PDB:1Q79}.
FT   TURN        325    328       {ECO:0000244|PDB:1Q79}.
FT   HELIX       331    352       {ECO:0000244|PDB:1Q79}.
FT   HELIX       358    361       {ECO:0000244|PDB:1Q79}.
FT   HELIX       367    370       {ECO:0000244|PDB:1Q79}.
FT   STRAND      372    383       {ECO:0000244|PDB:1Q79}.
FT   HELIX       384    395       {ECO:0000244|PDB:1Q79}.
FT   HELIX       398    406       {ECO:0000244|PDB:1Q79}.
FT   STRAND      411    416       {ECO:0000244|PDB:1Q79}.
FT   STRAND      428    430       {ECO:0000244|PDB:1Q78}.
FT   STRAND      433    443       {ECO:0000244|PDB:1Q79}.
FT   HELIX       457    473       {ECO:0000244|PDB:1Q79}.
FT   STRAND      482    489       {ECO:0000244|PDB:1Q79}.
FT   HELIX       490    493       {ECO:0000244|PDB:1Q79}.
FT   HELIX       494    496       {ECO:0000244|PDB:1Q79}.
SQ   SEQUENCE   739 AA;  82441 MW;  7C89C15E33232CFF CRC64;
     MPFPVTTQGS QQTQPPQKHY GITSPISLAA PKETDCLLTQ KLVETLKPFG VFEEEEELQR
     RILILGKLNN LVKEWIREIS ESKNLPQSVI ENVGGKIFTF GSYRLGVHTK GADIDALCVA
     PRHVDRSDFF TSFYDKLKLQ EEVKDLRAVE EAFVPVIKLC FDGIEIDILF ARLALQTIPE
     DLDLRDDSLL KNLDIRCIRS LNGCRVTDEI LHLVPNIDNF RLTLRAIKLW AKRHNIYSNI
     LGFLGGVSWA MLVARTCQLY PNAIASTLVH KFFLVFSKWE WPNPVLLKQP EECNLNLPVW
     DPRVNPSDRY HLMPIITPAY PQQNSTYNVS VSTRMVMVEE FKQGLAITDE ILLSKAEWSK
     LFEAPNFFQK YKHYIVLLAS APTEKQRLEW VGLVESKIRI LVGSLEKNEF ITLAHVNPQS
     FPAPKENPDK EEFRTMWVIG LVFKKTENSE NLSVDLTYDI QSFTDTVYRQ AINSKMFEVD
     MKIAAMHVKR KQLHQLLPSH VLQKKKKHST EGVKLTPLND SSLDLSMDSD NSMSVPSPTS
     AMKTSPLNSS GSSQGRNSPA PAVTAASVTN IQATEVSLPQ INSSESSGGT SSESIPQTAT
     QPAISSPPKP TVSRVVSSTR LVNPPPRPSG NAAAKIPNPI VGVKRTSSPH KEESPKKTKT
     EEDETSEDAN CLALSGHDKT ETKEQLDTET STTQSETIQT ATSLLASQKT SSTDLSDIPA
     LPANPIPVIK NSIKLRLNR
//
